Menu footer 1
Menu footer 2
Copyright © 2023 Organicell Regenerative Medicine, Inc. All rights reserved. Privacy Policy.
Our ground-breaking research in the field of nanotechnology, specifically extracellular vesicles and perinatal-derived nanoparticles, has created a novel biologic candidate that represents the next frontier of regenerative medicine. Organicell™ is committed to creating life changing and lifesaving therapies for important clinical conditions.
Organicell received approval from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application on our lead product, Zofin™, for the treatment of knee osteoarthritis. We completed a Phase 1 study for knee osteoarthritis and established the safery of our exosome therapeutics. A double blinded, placebo-controlled, phase II trial investigating the safety and efficacy of Zofin™ for patients suffering with knee osteoarthritis is planned for 2024
Organicell received approval from the (FDA) for an Investigational New Drug (IND) application on our lead product, Zofin™, in the treatment of patients diagnosed with COPD. This approved trial design will be a double blinded, placebo-controlled, phase I/II trial investigating the safety and potential efficacy of intravenous infusion (IV) of Zofin™ for the treatment of COPD.
Organicell has completed a Phase I in patients with moderate to severe COVID-19 as well as a separate Phase 1 study in patient with “long-haul” COVID-19. The FDA also granted the company an expanded access IND that provided additional patients with COVID-19 access to Zofin outside of the formal clinical trial. This expanded access protocol provides access to Zofin for patients in outpatient and inpatient facilities infected with SARS-CoV-2 who have mild to moderate COVID-19 infection, or who are judged by a healthcare provider to be at high risk of progression to moderate disease. The trial is being conducted at the United Memorial Medical Center in Houston, TX.
Organicell is committed to completing our FDA-approved clinical trials as we hope to develop an FDA-approved treatment for multiple clinical conditions.
To pioneer the frontiers of medical science through rigorous research, groundbreaking innovation, and the development of regenerative biologic therapies and nano-technologies to address a broad range of medical conditions.
To pioneer the frontiers of medical science through rigorous research, groundbreaking innovation, and the development of regenerative biologic therapies and nano-technologies to address a broad range of medical conditions.
We Believe We Have Found The Key To Consistent
Patient Outcomes
We Believe We Have Found The Key To Consistent
Patient Outcomes